Combination therapy in hormone-refractory prostate cancer.
Petrylak
D P
DP
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D000077143:Docetaxel; D004961:Estramustine / Q000008:administration & dosage; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D008297:Male; D017239:Paclitaxel / Q000031:analogs & derivatives / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids
D000893:Anti-Inflammatory Agents; D043823:Taxoids; D000077143:Docetaxel; D004961:Estramustine; D017239:Paclitaxel; D006854:Hydrocortisone